Enjaymo Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

enjaymo

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - Ónæmisbælandi lyf - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Beyfortus Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

beyfortus

astrazeneca ab - nirsevimab - Ónæmiskerfið sera og mótefni, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Spevigo Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - psoriasis - Ónæmisbælandi lyf - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Bimervax Umoja wa Ulaya - Kiaisilandi - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - bóluefni - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Influvactetra (Influvac Tetra) Stungulyf, dreifa í áfylltri sprautu 15/15/15/15 míkróg/skammt Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

influvactetra (influvac tetra) stungulyf, dreifa í áfylltri sprautu 15/15/15/15 míkróg/skammt

viatris aps - b/phuket/3073/2013-líkur stofn (b/phuket/3073/2013, villigerð); a/victoria/2570/2019 (h1n1)pdm09 - líkur stofn (a/victoria/2570/2019, ivr-215); a/darwin/9/2021 (h3n2)- líkur stofn (a/darwin/9/2021, san-010); b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - stungulyf, dreifa í áfylltri sprautu - 15/15/15/15 míkróg/skammt

Bupropion Teva Tafla með breyttan losunarhraða 300 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

bupropion teva tafla með breyttan losunarhraða 300 mg

teva b.v.* - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 300 mg

Actilyse Stungulyfs-/innrennslisstofn og leysir, lausn Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

actilyse stungulyfs-/innrennslisstofn og leysir, lausn

boehringer ingelheim international gmbh* - alteplasum inn - stungulyfs-/innrennslisstofn og leysir, lausn

Albuman Innrennslislyf, lausn 200 g/l Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

albuman innrennslislyf, lausn 200 g/l

prothya biosolutions netherlands b.v. - human serum albumin - innrennslislyf, lausn - 200 g/l

Albuman Innrennslislyf, lausn 40 g/l Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

albuman innrennslislyf, lausn 40 g/l

prothya biosolutions netherlands b.v. - human albumin - innrennslislyf, lausn - 40 g/l

Wellbutrin Retard Tafla með breyttan losunarhraða 150 mg Aislandi - Kiaisilandi - LYFJASTOFNUN (Icelandic Medicines Agency)

wellbutrin retard tafla með breyttan losunarhraða 150 mg

glaxosmithkline pharma a/s - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 150 mg